Long-circulating perfluorooctyl bromide nanocapsules for tumor imaging by 19FMRI

Diou, Odile; Tsapis, Nicolas; Giraudeau, Céline; Valette, Julien; Gueutin, Claire; Bourasset, Fanchon; Zanna, Sandrine; Vauthier, Christine; Fattal, Elias

doi:10.1016/j.biomaterials.2012.04.037

Cited by 72 publications

(67 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This significant enhancement in MRI signal occured over a much longer period than was observed in our previous studies, where the enhanced T 1 ‐weighted MRI signal had disappeared at 72 h PI of Mn‐LDH . It is suggested that modification of the nanoparticle surface with the PEG‐containing polymer can significantly prolong the blood circulation time and lead to much slower yet longer accumulation of nanoparticles in the tumor region via the enhanced permeability and retention (EPR) effect . These results, thus, indicate that Mn‐LDH@PFPE nanoparticles are promising pH‐activated imaging agents for specific in vivo imaging of breast cancer.…”

Section: Methodssupporting

confidence: 51%

Integrating Fluorinated Polymer and Manganese‐Layered Double Hydroxide Nanoparticles as pH‐activated ¹⁹F MRI Agents for Specific and Sensitive Detection of Breast Cancer

Zhang

Han

et al. 2019

Small

View full text Add to dashboard Cite

19F magnetic resonance imaging (19F MRI) agents capable of being activated upon interactions with cancer triggers are attracting increasing attention, although challenges still remain for precise and specific detection of cancer tissues. In this study, a novel hybrid 19F MRI agent for pH‐sensitive detection of breast cancer tissues is reported, a composite system designed by conjugating a perfluoropolyether onto the surface of manganese‐incorporated layered double hydroxide (Mn‐LDH@PFPE) nanoparticles. The 19F NMR/MRI signals from aqueous solutions of Mn‐LDH@PFPE nanoparticles are quenched at pH 7.4, but “turned on” following a reduction in pH to below 6.5. This is due to partial dissolution of Mn2+ from the Mn‐LDH nanoparticles and subsequent reduction in the effect of paramagnetic relaxation. Significantly, in vivo experiments reveal that an intense 19F MR signal can be detected only in the breast tumor tissue after intravenous injection of Mn‐LDH@PFPE nanoparticles due to such a specific activation. Thus pH‐activated Mn‐LDH@PFPE nanoparticles are a potential “smart” 19F MRI agent for precise and specific detection of cancer diseases.

show abstract

Section: Methodssupporting

confidence: 51%

Integrating Fluorinated Polymer and Manganese‐Layered Double Hydroxide Nanoparticles as pH‐activated ¹⁹F MRI Agents for Specific and Sensitive Detection of Breast Cancer

Zhang

Han

et al. 2019

Small

View full text Add to dashboard Cite

show abstract

“…The optical imaging of an unrelated, integrin-targeting PFC-NIR formulation has previously been used to study tumor vasculature 46 . Fluorine-based MRI has also previously been used to investigate tumors, but a microscopic evaluation of the cellular distribution of the reagent was not performed 47 . The magnetic relaxation of some PFCs is sensitive to the oxygen content of surrounding tissue, and several investigators have studied oxygen content within the tumor in a non-invasive fashion 48 - 51 .…”

Section: Discussionmentioning

confidence: 99%

A novel probe for the non-invasive detection of tumor-associated inflammation

et al. 2013

View full text Add to dashboard Cite

A novel dual-mode contrast agent was formulated through the addition of an optical near infrared (NIR) probe to a perfluorocarbon (PFC)-based 19F magnetic resonance imaging (MRI) agent, which labels inflammatory cells in situ. A single PFC-NIR imaging agent enables both a qualitative, rapid optical monitoring of an inflammatory state and a quantitative, detailed and tissue-depth independent magnetic resonance imaging (MRI). The feasibility of in vivo optical imaging of the inflammatory response was demonstrated in a subcutaneous murine breast carcinoma model. Ex vivo optical imaging was used to quantify the PFC-NIR signal in the tumor and organs, and results correlated well with quantitative 19F NMR analyses of intact tissues. 19F MRI was employed to construct a three-dimensional image of the cellular microenvironment at the tumor site. Flow cytometry of isolated tumor cells was used to identify the cellular localization of the PFC-NIR probe within the tumor microenvironment. Contrast is achieved through the labeling of host cells involved in the immune response, but not tumor cells. The major cellular reservoir of the imaging agent were tumor-infiltrating CD11b+ F4/80low Gr-1low cells, a cell subset sharing immunophenotypic features with myeloid-derived suppressor cells (MDSCs). These cells are recruited to sites of inflammation and are implicated in immune evasion and tumor progression. This PFC-NIR contrast agent coupled to non-invasive, quantitative imaging techniques could serve as a valuable tool for evaluating novel anticancer agents.

show abstract

“…Among all the MI methods, MRI is the most frequently used method for therapeutics owing to its very high resolution and capability to cover most of the organs. More importantly, many MRI contrast agents can be encapsulated into NPs . Optical imaging can also be utilized as a medical imaging modality in nanotheranostics; however, the application of optical imaging is limited owing to the visible light spectrum scattering in the soft tissues region.…”

Section: Applicationsmentioning

confidence: 99%

Polymeric nanoparticles: the future of nanomedicine

Banik

Fattahi

Brown

2015

WIREs Nanomed Nanobiotechnol

386

235

View full text Add to dashboard Cite

Polymeric nanoparticles (NPs) are one of the most studied organic strategies for nanomedicine. Intense interest lies in the potential of polymeric NPs to revolutionize modern medicine. To determine the ideal nanosystem for more effective and distinctly targeted delivery of therapeutic applications, particle size, morphology, material choice, and processing techniques are all research areas of interest. Utilizations of polymeric NPs include drug delivery techniques such as conjugation and entrapment of drugs, prodrugs, stimuli-responsive systems, imaging modalities, and theranostics. Cancer, neurodegenerative disorders, and cardiovascular diseases are fields impacted by NP technologies that push scientific boundaries to the leading edge of transformative advances for nanomedicine.

show abstract

Long-circulating perfluorooctyl bromide nanocapsules for tumor imaging by 19FMRI

Cited by 72 publications

References 49 publications

Integrating Fluorinated Polymer and Manganese‐Layered Double Hydroxide Nanoparticles as pH‐activated ¹⁹F MRI Agents for Specific and Sensitive Detection of Breast Cancer

Integrating Fluorinated Polymer and Manganese‐Layered Double Hydroxide Nanoparticles as pH‐activated ¹⁹F MRI Agents for Specific and Sensitive Detection of Breast Cancer

A novel probe for the non-invasive detection of tumor-associated inflammation

Polymeric nanoparticles: the future of nanomedicine

Contact Info

Product

Resources

About

Long-circulating perfluorooctyl bromide nanocapsules for tumor imaging by 19FMRI

Cited by 72 publications

References 49 publications

Integrating Fluorinated Polymer and Manganese‐Layered Double Hydroxide Nanoparticles as pH‐activated 19F MRI Agents for Specific and Sensitive Detection of Breast Cancer

Integrating Fluorinated Polymer and Manganese‐Layered Double Hydroxide Nanoparticles as pH‐activated 19F MRI Agents for Specific and Sensitive Detection of Breast Cancer

A novel probe for the non-invasive detection of tumor-associated inflammation

Polymeric nanoparticles: the future of nanomedicine

Contact Info

Product

Resources

About

Integrating Fluorinated Polymer and Manganese‐Layered Double Hydroxide Nanoparticles as pH‐activated ¹⁹F MRI Agents for Specific and Sensitive Detection of Breast Cancer

Integrating Fluorinated Polymer and Manganese‐Layered Double Hydroxide Nanoparticles as pH‐activated ¹⁹F MRI Agents for Specific and Sensitive Detection of Breast Cancer